ImmunityBio, Inc. (IBRX) - Dilution Analysis

10-Q filing | 1026.9M shares outstanding

10-Q filing | 946.6M shares outstanding

10-Q filing | 888.2M shares outstanding

10-Q filing | 853.2M shares outstanding

10-K filing | 853.4M shares outstanding

10-Q filing | 695.9M shares outstanding

10-Q filing | 686.9M shares outstanding

10-Q filing | 672.8M shares outstanding

S-3 filing: This prospectus relates to the offer and sale from time to time by the selling stockholders named in this prospectus or their permitted transferees (the selling stockholders) of (i) 2,432,894 shares of our common stock, $0.0001 par value per share (the common stock) and (ii) up to $10,000,000 of shares of our common stock (the Option Shares) that are issuable upon exercise of an option, at a price per share to be determined by the30-day trailing volume weighted average price of the common stock, calculated from the date of exercise (the Option), granted pursuant to the Stock Purchase and Option Agreement, dated as of December 29, 2023, by and between ImmunityBio, Inc. and the selling stockholders named therein (the Option Agreement).

10-K filing | 674.0M shares outstanding

10-Q filing | 667.7M shares outstanding

8-K filing: ImmunityBio, Inc. executed a $200.0 million convertible promissory note with Nant Capital, LLC and exchanged existing convertible promissory notes representing approximately $270 million in aggregate principal amount and accrued and unpaid interest for 209,291,936 shares of Common Stock.

10-Q filing | 437.5M shares outstanding

10-Q filing | 428.4M shares outstanding

10-K filing | 399.9M shares outstanding

S-3 filing: The filing is for a shelf offering of common stock, preferred stock, debt securities, depositary shares, warrants to purchase common stock, preferred stock or debt securities, subscription rights, purchase contracts or any combination of the foregoing, either individually or as units comprised of one or more of the other securities up to $750,000,000.

10-Q filing | 400.1M shares outstanding

10-Q filing | 398.0M shares outstanding

10-Q filing | 397.9M shares outstanding

POS AM filing: ImmunityBio, Inc. has entered into an open market sale agreement with Jefferies LLC to offer and sell shares of its common stock having an aggregate offering price of up to $500,000,000 from time to time.

10-K filing | 389.2M shares outstanding

10-Q filing | 391.9M shares outstanding

10-Q filing | 391.2M shares outstanding

POS AM filing: This prospectus relates to up to 1,094,377 shares of Common Stock that may be issued upon the exercise of stock options granted to certain employees of ImmunityBio Private under the Assumed Plan who are no longer service providers.

10-Q filing | 383.9M shares outstanding

10-K filing | 109.3M shares outstanding

10-Q filing | 108.6M shares outstanding

10-Q filing | 108.0M shares outstanding

10-Q filing | 98.5M shares outstanding

10-K filing | 98.5M shares outstanding